Moleculin Biotech (MBRX) Sets New 1-Year Low at $1.39

Moleculin Biotech Inc (NASDAQ:MBRX) reached a new 52-week low during mid-day trading on Monday . The company traded as low as $1.39 and last traded at $1.40, with a volume of 500 shares trading hands. The stock had previously closed at $1.53.

The company has a market cap of $42.98 million, a PE ratio of -3.07 and a beta of -0.79.

Moleculin Biotech (NASDAQ:MBRX) last posted its earnings results on Monday, August 13th. The company reported ($0.20) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.06). On average, equities analysts expect that Moleculin Biotech Inc will post -0.57 earnings per share for the current fiscal year.

An institutional investor recently bought a new position in Moleculin Biotech stock. CIBC World Markets Inc. purchased a new position in Moleculin Biotech Inc (NASDAQ:MBRX) during the 1st quarter, according to its most recent filing with the Securities & Exchange Commission. The fund purchased 64,850 shares of the company’s stock, valued at approximately $117,000. CIBC World Markets Inc. owned approximately 0.25% of Moleculin Biotech at the end of the most recent quarter. 4.78% of the stock is owned by institutional investors.

Moleculin Biotech Company Profile (NASDAQ:MBRX)

Moleculin Biotech, Inc, a clinical-stage pharmaceutical company, focuses on the development of oncology drug candidates. Its lead drug candidate is liposomal Annamycin, an anthracycline intended for the treatment of relapsed or refractory acute myeloid leukemia (AML). The company also develops WP1066 Portfolio, an immuno-stimulating STAT3 inhibitor for the treatment of brain tumors, pancreatic cancer, and AML; and WP1122 Portfolio and related molecules for the treatment of glioblastoma multiforme and related central nervous system malignancies.

See Also: How to Profit and Limit Losses With Stop Orders

Receive News & Ratings for Moleculin Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Moleculin Biotech and related companies with's FREE daily email newsletter.

Leave a Reply